Use of biomarkers for detecting ovarian cancer
AssigneesVermillion, Inc., The Johns Hopkins University
InventorsDaniel W. Chan, Zhen P. Zhang, Eric Fung, Xiao-Ying Meng
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.
Claims12
1-77. (canceled)
A panel for characterizing ovarian cancer comprising biomarkers CA125 and HE4.
The panel of claim 1, further comprising biomarker prealbumin.
The panel of claim 2, further comprising a biomarker selected from the group consisting of CA125 II, CA15-3, CA19-9, CA72-4, CA 195, tumor associated trypsin inhibitor (TATI), CEA, placental alkaline phosphatase (PLAP), Sialyl TN, galactosyltransferase, macrophage colony stimulating factor (M-CSF, CSF-1), lysophosphatidic acid (LPA), 110 kD component of the extracellular domain of the epidermal growth factor receptor (p110EGFR), tissue kallikreins, kallikrein 6 and kallikrein 10 (NES-1), prostasin, creatine kinase B (CKB), LASA, HER-2/neu, urinary gonadotropin peptide, Dianon NB 70/K, Tissue peptide antigen (TPA), osteopontin and haptoglobin, and protein variants of the markers.
A solid support comprising at least two capture molecules each of which specifically binds biomarkers CA125 and HE4.
A panel of capture molecules each of which specifically binds biomarkers CA125 and HE4.
Dependencies are inferred from the claim text.